Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Bortezomib in Treating Patients With Lymphoproliferative Disorders
Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders
Status: Enrolling
Updated:  11/2/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders
Status: Enrolling
Updated: 11/2/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated:  11/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated: 11/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)
Status: Enrolling
Updated:  11/3/2015
Fox Chase Cancer Center
mi
from
Rockledge, PA
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)
Status: Enrolling
Updated: 11/3/2015
Fox Chase Cancer Center
mi
from
Rockledge, PA
Click here to add this to my saved trials
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma
Status: Enrolling
Updated:  11/3/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma
Status: Enrolling
Updated: 11/3/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
City of Hope National Medical Center
mi
from
Duarte, CA
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Stanford University Medical Center
mi
from
Palo Alto, CA
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Rocky Mountain Cancer Center
mi
from
Denver, CO
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Georgetown University
mi
from
Washington,
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
University of Miami
mi
from
Miami, FL
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Loyola University Medical Center, Cardinal Bernardin Cancer Center
mi
from
Maywood, IL
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Loyola University Medical Center, Cardinal Bernardin Cancer Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Washington University School of Medicine
mi
from
St. Louis, MO
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Weill-Cornell Medical College
mi
from
New York, NY
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Ohio State University
mi
from
Columbus, OH
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Oregon Health and Science University
mi
from
Portland, OR
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Baylor Sammons Cancer Center
mi
from
Dallas, TX
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
Univ of Washington
mi
from
Seattle, WA
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated:  11/6/2015
UZ Gasthuisberg
mi
from
Leuven,
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status: Enrolling
Updated: 11/6/2015
UZ Gasthuisberg
mi
from
Leuven,
Click here to add this to my saved trials
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Ofatumumab and Bendamustine in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
Status: Enrolling
Updated:  11/10/2015
Georgetown University
mi
from
Washington,
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Ofatumumab and Bendamustine in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
Status: Enrolling
Updated: 11/10/2015
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients With High Risk B-cell CLL/SLL
Status: Enrolling
Updated:  11/10/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients With High Risk B-cell CLL/SLL
Status: Enrolling
Updated: 11/10/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  11/11/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 11/11/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  11/11/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 11/11/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Simvastatin in Waldenstrom's Macroglobulinemia
Phase II Study of Simvastatin in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  11/11/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Simvastatin in Waldenstrom's Macroglobulinemia
Phase II Study of Simvastatin in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 11/11/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
Phase I Trial to Assess Safety and Immunogenicity of Xenogeneic CD20 DNA Vaccination With Patients With B-Cell Lymphoma
Status: Enrolling
Updated:  11/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
Phase I Trial to Assess Safety and Immunogenicity of Xenogeneic CD20 DNA Vaccination With Patients With B-Cell Lymphoma
Status: Enrolling
Updated: 11/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Status: Enrolling
Updated:  11/16/2015
Stanford University Cancer Institute
mi
from
Stanford, CA
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Status: Enrolling
Updated: 11/16/2015
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
City of Hope National Medical Center
mi
from
Duarte, CA
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Colorado Blood Cancer Institute
mi
from
Denver, CO
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Loyola University Medical Center - Cardinal Bernadin Cancer Center
mi
from
Maywood, IL
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Loyola University Medical Center - Cardinal Bernadin Cancer Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
St. Francis Medical Group Oncology and Hematology Specialists
mi
from
Indianapolis, IN
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
St. Francis Medical Group Oncology and Hematology Specialists
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Seattle Cancer Care Alliance/University of Washington Medical Center
mi
from
Seattle, WA
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Seattle Cancer Care Alliance/University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Stanford Cancer Center
mi
from
Stanford, CA
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
University of Miami, Miller School of Medicine - Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
University of Miami, Miller School of Medicine - Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Washington University School of Medicine
mi
from
St. Louis, MO
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
NYU Clinical Cancer Center
mi
from
New York, NY
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Columbia University Medical Center
mi
from
New York, NY
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials